Moreover, recent studies suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer-associated genes BRCA1 and BRCA2 (36). This evidence concerns the gene BRCA2 and breast carcinoma.